Skip to content

Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis (MS)

Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05252195
Enrollment
300
Registered
2022-02-23
Start date
2022-05-24
Completion date
2027-03-31
Last updated
2025-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Cognitive dysfunction

Brief summary

The researchers will use technology-assisted ambulatory assessment techniques to examine cognitive dysfunction in people with Multiple Sclerosis (MS). The researchers will determine if ambulatory assessments are sensitive to subtle declines in cognitive functioning. They will also explore the impact of modifiable factors, such as sleep, physical activity, mood, and somatic symptoms on cognitive function. These efforts will uncover behavioral and medical intervention methods. Finally, they will explore whether variability in cognitive functioning predicts short- and long-term changes in other patient-centered functional domains, social participation and physical functioning.

Interventions

None listed

Sponsors

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
Wayne State University
CollaboratorOTHER
University of Washington
CollaboratorOTHER
University of Michigan
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Are able to fluently converse and read in English. 2. Multiple Sclerosis (MS) diagnosis (confirmed from neurologist, all relapsing and progressive subtypes included) 3. Ambulate either independently or with the use of a cane or walker (or similar device) for at least 50% of the time at baseline

Exclusion criteria

1. MS relapse within the past 30 days (may become eligible after 30 days; criteria used at T1, T2, and T3). 2. Inability to use study data collection tools (i.e., ActiGraph wrist-worn activity watch, smart phone app).

Design outcomes

Primary

MeasureTime frameDescription
Change in Cognitive Function - Ambulatory measurement via Dot Memory TestBaseline up to year 2Reported in terms of Euclidian distance/error Cognition Covariates may include: age, sex, disease duration, Multiple Sclerosis (MS) subtype (relapsing vs. progressive subtypes combined), personality variables, and cognitive reserve (education plus scores on test of vocabulary).
Change in Cognitive Function - Ambulatory measurement via Symbol Search TestBaseline up to year 2Reported in Reaction Time (milliseconds) Cognition Covariates may include: age, sex, disease duration, Multiple Sclerosis (MS) subtype (relapsing vs. progressive subtypes combined), personality variables, and cognitive reserve (education plus scores on test of vocabulary).
Change in Cognitive Function - clinic-based neurocognitive measurement via NIH Toolbox Cognitive BatteryBaseline up to year 2Test Battery reported in T-scores. Covariates may include: age, sex, disease duration, MS subtype (relapsing vs. progressive subtypes combined), personality variables, and cognitive reserve (education plus scores on test of vocabulary).
Change in Cognitive Function - clinic-based neurocognitive measurement via Symbol Digit Modalities testBaseline up to year 2Covariates may include: age, sex, disease duration, MS subtype (relapsing vs. progressive subtypes combined), personality variables, and cognitive reserve (education plus scores on test of vocabulary). The score is the number of correct answers in 90 seconds. Higher scores indicates better attention and processing speed.
Change in Cognitive Function - clinic-based neurocognitive measurement via Paced Auditory Serial Addition TestBaseline up to year 2Covariates may include: age, sex, disease duration, MS subtype (relapsing vs. progressive subtypes combined), personality variables, and cognitive reserve (education plus scores on test of vocabulary). The score range is 0-60 and higher numbers indicate better sustained attention, speed of information processing, and working memory.
Change in Cognitive Function - clinic-based neurocognitive measurement via Rey Auditory Verbal Learning TestBaseline up to year 2Covariates may include: age, sex, disease duration, MS subtype (relapsing vs. progressive subtypes combined), personality variables, and cognitive reserve (education plus scores on test of vocabulary). The scores from the test represent the total immediate recall (over 5 learning trials), delayed recall, and recognition. Higher scores indicate better verbal learning and memory.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026